A practical reference on purity: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | G-protein-coupled receptor on pituitary somatotrophs |
| Half-life, long-acting form | Several days | Extended by covalent albumin binding |
| Half-life, short form | About 30 minutes | Cleared rapidly by peptidases and kidneys |
| Route in studies | Subcutaneous injection | Used in the published human trials |
| Main measured effect | Rise in GH and IGF-1 | Surrogate markers rather than clinical endpoints |
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
Variational autoencoders (VAEs) are deep learning models that probabilistically encode data. They are typically used for tasks such as noise reduction from images, data compression, identifying unusual patterns, and facial recognition. Unlike standard autoencoders, which compress input data into a fixed latent representation, VAEs model the latent space as a probability distribution, allowing for smooth sampling and interpolation between data points. The encoder ("recognition model") maps input data to a latent space, producing means and variances that define a probability distribution. The decoder ("generative model") samples from this latent distribution and attempts to reconstruct the original input.
=== Post-injection delirium/sedation syndrome === Post-injection delirium/sedation syndrome (PDSS) is a serious adverse event previously considered specific to olanzapine pamoate (Zyprexa Relprevv) among LAI antipsychotics. PDSS is characterized by heavy sedation, possible coma, and/or delirium following injection, believed to result from inadvertent intravascular drug entry. Early industry-sponsored analyses of clinical trial and post-marketing databases found no cases of PDSS in patients receiving paliperidone palmitate across 10 completed trials (3,817 subjects, 33,906 injections), leading to the conclusion that PDSS was not associated with paliperidone palmitate. However, a 2024 post-marketing case report published in the Journal of Clinical Psychopharmacology documented a case of PDSS following paliperidone palmitate administration. A 48-year-old male patient with bipolar affective disorder received two 234 mg loading doses of paliperidone palmitate (Invega Sustenna) one week apart. Two days after the second injection, he developed trembling, rigidity, weakness, and drowsiness. His symptoms worsened over the following days to include slurred speech and difficulty walking and talking. The authors recommended routine measurement of baseline antipsychotic blood levels as part of long-acting injectable management to help identify patients at elevated risk.
Further testing in a microfluidic blood vessel model lined with human endothelial cells showed that pNPs triggered a self-amplifying coagulation-like process, forming nanofibrous structures that occluded sections of the artificial vessel. These findings suggest that pNPs could serve as a synthetic alternative for enhancing clot formation and improving hemorrhage management in trauma care.
=== China, Russia === In 2013, Russia and China banned ractopamine in pork, and Russia also in beef, deeming it unfit for human consumption. Because the traditional Chinese diet embraces pig offal, and because ractopamine is concentrated by the gastro-intestinal system of animals, Chinese officials have banned ractopamine. Other countries in Asia, whose traditional diet is similar to that of the Chinese, have had similar concerns, but the American use of tied trade access as a proxy for conflict has somewhat mitigated their reactions.
=== Functional categorization === Nonsense mutations include stop-gain and start-loss. Stop-gain is a mutation that results in a premature termination codon (a stop was gained), which signals the end of translation. This interruption causes the protein to be abnormally shortened. The number of amino acids lost mediates the impact on the protein's functionality and whether it will function whatsoever. Stop-loss is a mutation in the original termination codon (a stop was lost), resulting in abnormal extension of a protein's carboxyl terminus. Start-gain creates an AUG start codon upstream of the original start site. If the new AUG is near the original start site, in-frame within the processed transcript and downstream to a ribosomal binding site, it can be used to initiate translation. The likely effect is additional amino acids added to the amino terminus of the original protein. Frame-shift mutations are also possible in start-gain mutations, but typically do not affect translation of the original protein. Start-loss is a point mutation in a transcript's AUG start codon, resulting in the reduction or elimination of protein production. Missense mutations code for a different amino acid. A missense mutation changes a codon so that a different protein is created, a non-synonymous change. Conservative mutations result in an amino acid change. However, the properties of the amino acid remain the same (e.g., hydrophobic, hydrophilic, etc.) At times, a change to one amino acid in the protein is not detrimental to the organism as a whole.
Sources: en.wikipedia.org
A change in pressure at any point in an enclosed incompressible fluid at rest is transmitted equally and undiminished to all points in all directions throughout the fluid, and the force due to the pressure acts at right angles to the enclosing walls.
== Nutrition == NATO bases the nutritional content requirement on a reference soldier weighing 79 kg (174 lb), who on normal operations would have an energy expenditure of approximately 3,600 kcal per day. For combat operations, energy expenditure is estimated to be 4,900 kcal per day; however, this is seen to be a worst-case scenario.
An animal in a study that does not receive the treatment being tested. Comparing the health of control animals with the health of treated animals allows researchers to evaluate the effects of a treatment more accurately. (NCI) Control group
=== Cameos === Charlize Theron made a cameo appearance as Stormfront in the fictional film within the series Dawn of the Seven in the episode "Payback". Billy Zane portrayed Alastair Adana in another fictional film within the series Not Without My Dolphin. Jaz Sinclair appeared ahead of starring in the spinoff series Gen V in a photograph as Marie Moreau for the episode "The Only Man in the Sky". Seth Rogen portrayed himself as the SupePorn.com patron "SirCumsALot779" in the episode "The Last Time to Look on This World of Lies". Uncredited Patton Oswalt, Josh Gad, Ashton Kutcher, Mila Kunis, Elizabeth Banks, Kumail Nanjiani, Aisha Tyler, and Rose Byrne appeared as fictionalized versions of themselves parodying Gal Gadot's universally panned COVID-19 lockdown celebrity supergroup cover of "Imagine", in the order of their appearance respectively singing on YouTube for the opening scene of the episode "Herogasm".
Sources: en.wikipedia.org
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.
The drug affinity complex links the peptide to serum albumin through a covalent bond. The conjugate is too large to be filtered quickly by the kidneys and is shielded from enzymatic breakdown. This extends the apparent half-life from roughly minutes to several days.
Long-term safety and any clinical benefit are unestablished. Published human data cover small groups over limited periods and focus on hormone levels rather than health outcomes. Whether prolonged elevation of growth hormone and insulin-like growth factor 1 is beneficial or harmful is an open question.
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.